The online gathering attracted more than 100 professionals from across the country working in pharma sector and attended by leading organisations, associations and prominent government policymakers of the country
A panel discussion on “Mucormycosis (Black Fungus) prevention, treatment and effect on post-COVID-19 patients” was organised by the Faculty of Pharmacy, Dehradun Institute of Technology (DIT) University, in collaboration with the Indian Pharmaceutical Association-Delhi State Branch (IPADSB) virtually recently, a statement said.
The programme was chaired by Prof (Dr) Jagannath Sahoo, Director, Faculty of Pharmacy, School of Pharmacy and Population Health Informatics (SoPPHI), DIT University; convened by Prof (Dr) Havagiray Chitme, Head of Department, Faculty of Pharmacy, DIT University; coordinated by Samir Bhargava, Assistant Professor, Faculty of Pharmacy, DIT University; and moderated by Dr Bhavna, Associate Professor, Faculty of Pharmacy, DIT University, it added.
According to the statement, the online gathering attracted more than 100 professionals from across the country working in pharma sector and attended by leading organisations, associations and prominent government policymakers of the country, apart from students.
The first scientific talk was delivered by Dr Mathew Varghese, Head, Department of Orthopaedics, St Stephen’s Hospital, Delhi, on the topic ‘Origin of mucormycosis and its treatment.’ He spoke on basic pathophysiology and clinical features of mucormycosis.
Dr Varghese also explained the relationship of immunomodulators and mucormycosis. He said, “The use of antibiotics and immunomodulators make human beings more vulnerable to mucormycosis.”
He also talked on other possible reasons of developing mucormycosis like use of industrial oxygen, antibiotics and steroids.
Dr Shailesh Kothalkar, Consultant, ENT, Head and Neck Surgeon, Seven Star Hospital, Nagpur, Maharashtra gave an overview of ‘allopathic aspect of treatment in mucormycosis’ and shared endoscopic features of the disease. He also explained the surgical procedure of mucormycosis in brief, the statement said.
The last virtual talk was deliberated by Dr Piyush Juneja, Ayurvedic Consultant, wherein he discussed the various aspects of Ayurveda for the treatment and management of COVID-19 and mucormycosis. He also suggested the pharma fraternity to take up the ideas from Ayurveda for future research of POC (proof-of-concept), added the statement.